Drug: SL-172154
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cutaneous Squamous Cell Carcinoma
Conditions
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Trial Timeline
Sep 17, 2020 → Apr 8, 2022
NCT ID
NCT04502888About Drug: SL-172154
Drug: SL-172154 is a phase 1 stage product being developed by Shattuck Labs for Cutaneous Squamous Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04502888. Target conditions include Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck.
What happened to similar drugs?
7 of 20 similar drugs in Cutaneous Squamous Cell Carcinoma were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04502888 | Phase 1 | Terminated |
Competing Products
20 competing products in Cutaneous Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONTAK (denileukin difitox, DAB389IL-2) | Eisai | Approved | 43 |
| ONTAK | Eisai | Approved | 43 |
| E7777 9 mcg/kg | Eisai | Phase 3 | 40 |
| ONTAK | Eisai | Approved | 43 |
| Mogamulizumab | Kyowa Kirin | Approved | 47 |
| Mogamulizumab + Brentuximab vedotin | Kyowa Kirin | Phase 1 | 36 |
| Mogamulizumab | Kyowa Kirin | Phase 2 | 39 |
| KW-0761 + Vorinostat | Kyowa Kirin | Phase 3 | 40 |
| Enzastaurin | Eli Lilly | Phase 2 | 35 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Comparator: vorinostat | Merck | Pre-clinical | 26 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| TR701 FA | Merck | Phase 2 | 35 |
| MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Merck | Phase 2 | 35 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Tulisokibart + Placebo | Merck | Phase 2 | 39 |
| Aspirin + Ipilimumab + Pembrolizumab | Merck | Phase 2 | 35 |
| Pembrolizumab + Mogamulizumab | Merck | Phase 2 | 42 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |